PUBLIC COMPANY
save$PMNProMIS Neurosciences Inc.
$PMNToronto, Ontario, CAupdated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatmentDid the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?stat · 3h ago
- STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trialSellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.stat · 2d ago
- STAT+: What to know about Biogen’s big lupus study readoutBiogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.stat · 7d ago
- STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problemAlnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.stat · 7d ago
- STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapyNovartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.stat · 13d ago
- STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapyNovartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.stat · 13d ago
- STAT+: A possible comeback for a failed sickle cell gene therapyThree years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…stat · 13d ago
- STAT+: Beyond statins, one drug lowered heart attack risk by 20%A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."stat · 14d ago
- STAT+: Medicare delays controversial remote patient monitoring rule to 2029Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.stat · 14d ago
- STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debutRasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.stat · 14d ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that